Company intelligence
Advection
Accelerating Access Through Digital Innovations
About Advection
At Advection, we help our clients clear the fog, turning HEOR and Market Access complexity into clarity. We are a strategic partner to life science companies, guiding you through the US and global payer landscapes with confidence. From early evidence planning to value demonstration, we simplify the path to patient access and help your innovations reach the patients who need them most. Advection was founded in April 2025 by two experienced pharmacists and HEOR professionals with a shared commitment to advancing healthcare through Innovation, Community, and Value. Our work is grounded in real-world global experience, enhanced by AI through our own digital innovations, and driven by a belief that better decisions lead to better outcomes. With our headquarters in California and a strategic operations base in New Jersey, we offer responsive and collaborative support to clients across the United States and around the world. Let’s accelerate access, unlock value, and build a healthier future together.
Verified activity
Signals from Advection
5 published signals
Research & Knowledge
Advection published updates on CareFirst’s CVS Caremark clinical criteria for wet AMD authorization duration and ophthalmologist requirements.
Reported by Justin Yu
Research & Knowledge
Advection published a poster on the mean cumulative treatment intensity of 14.1 injections over five years among 7,811 patients with nAMD in Taiwan.
Reported by Justin Yu
Research & Knowledge
Advection published a poster on a six-month nonrandomized comparison of 99 treatment-naïve eyes where 78.1% treated with aflibercept 8 mg and 49.3% treated with faricimab reached a 12-week interval.
Reported by Justin Yu
Research & Knowledge
Advection published a meta-analysis of 21 studies, including 9 randomized trials, finding that residual subretinal fluid is associated with better baseline vision but not greater visual improvement during anti-VEGF therapy.
Reported by Justin Yu
Research & Knowledge
Advection published a poster on the policy change in Taiwan where patients received 14.7 injections over three years following expansion of anti-VEGF reimbursement.
Reported by Justin Yu